NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529 ext. 7980.
The investigation focuses on whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
On March 28, 2022, NeoGenomics issued a press release announcing that its Chief Executive “will step down as CEO and member of the Board of Directors, effective immediately.” The company further stated that it “expects first-quarter 2022 revenue to be below the lower bound of its prior guidance of $118-120 million and first-quarter 2022 EBITDA to be lower than the lower bound of its earlier forecast of ($(15) to ($(15)12) million. NeoGenomics also revealed that “[t]The larger than expected EBITDA loss was primarily due to a higher than expected cost of goods sold for clinical services” and that it “withdrew its 2022 annual financial guidance issued on February 23, 2022”.
On this news, NeoGenomics stock price fell $5.30 per share, or 29.79%, to close at $12.49 per share on March 29, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading firms in the areas of corporate litigation, securities and antitrust. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he established, fighting for the rights of victims of securities fraud, breaches of fiduciary duty and corporate misconduct. The firm recovered numerous multimillion-dollar damages on behalf of class members. To see www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980